Insights

Emerging Diagnostics Customer segment and product focus on rapid molecular diagnostics for COVID-19 with an EUA-authorized test and molecular detector, presenting a market entry point for hospital labs, urgent care networks, and regional clinics seeking faster results.

Speed to Action Value proposition centers on delivering lab-quality results in minutes, offering a compelling selling point to facilities aiming to reduce patient wait times, increase test throughput, and improve patient flow.

Early Sales Signal Recent leadership hire in sales and marketing indicates a push to scale commercial efforts; target accounts may include large diagnostics distributors, urgent care chains, and outpatient imaging centers that stock molecular tests.

Regulatory Position EUA authorization provides a compelled case to engage with mid-to-large labs and public health partners seeking compliant, near-term testing solutions, while preparing for broader regulatory pathways and potential product expansion.

Growth Readiness Funding level and revenue range suggest a small, agile organization with potential for channel partnerships, co-development with contract manufacturers, and joint ventures to scale production and distribution.

Similar companies to Anavasi Diagnostics®

Anavasi Diagnostics® Tech Stack

Anavasi Diagnostics® uses 8 technology products and services including Open Graph, Squarespace, Cart Functionality, and more. Explore Anavasi Diagnostics®'s tech stack below.

  • Open Graph
    Content Management System
  • Content Management System
  • Cart Functionality
    E-commerce
  • Stimulus
    Javascript Frameworks
  • Choices
    Javascript Libraries
  • HSTS
    Security
  • Google Tag Manager
    Tag Management

Anavasi Diagnostics®'s Email Address Formats

Anavasi Diagnostics® uses at least 1 email format:
Anavasi Diagnostics® Email FormatsExamplePercentage
First.Last@anavasidx.comJohn.Doe@anavasidx.com
100%

Frequently Asked Questions

What is Anavasi Diagnostics®'s official website and social media links?

Minus sign iconPlus sign icon
Anavasi Diagnostics®'s official website is anavasidx.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Anavasi Diagnostics® generate?

Minus sign iconPlus sign icon
As of October 2026, Anavasi Diagnostics®'s annual revenue is estimated to be $1M - $10M.

What is Anavasi Diagnostics®'s NAICS code?

Minus sign iconPlus sign icon
Anavasi Diagnostics®'s NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does Anavasi Diagnostics® have currently?

Minus sign iconPlus sign icon
As of October 2026, Anavasi Diagnostics® has approximately 9 employees across 1 continents, including North America. Key team members include Regional Business Manager: J. Y. Explore Anavasi Diagnostics®'s employee directory with LeadIQ.

What industry does Anavasi Diagnostics® belong to?

Minus sign iconPlus sign icon
Anavasi Diagnostics® operates in the Medical Equipment Manufacturing industry.

What technology does Anavasi Diagnostics® use?

Minus sign iconPlus sign icon
Anavasi Diagnostics®'s tech stack includes Open Graph, Squarespace, Cart Functionality, Squarespace Commerce, Stimulus, Choices, HSTS and Google Tag Manager.

What is Anavasi Diagnostics®'s email format?

Minus sign iconPlus sign icon
Anavasi Diagnostics®'s email format typically follows the pattern of First.Last@anavasidx.com. Find more Anavasi Diagnostics® email formats with LeadIQ.

How much funding has Anavasi Diagnostics® raised to date?

Minus sign iconPlus sign icon
As of October 2026, Anavasi Diagnostics® has raised $24M in funding. The last funding round occurred on Jan 12, 2022 for $2.6M.

When was Anavasi Diagnostics® founded?

Minus sign iconPlus sign icon
Anavasi Diagnostics® was founded in 2020.
Anavasi Diagnostics® logo

Anavasi Diagnostics®

Medical Equipment ManufacturingWashington, United States2-10 Employees

Anavasi Diagnostics is a medical equipment manufacturer focused on molecular diagnostic testing for infectious diseases, with its initial emphasis on COVID-19. The company aims to provide rapid, precise, and affordable tests that deliver lab-quality results within minutes to support timely clinical decisions. Its leading offerings, the AscencioDx Covid-19 Test and the AscencioDx Molecular Detector, are designed to yield a COVID-19 diagnosis in under 30 minutes on average using a painless lower-nasal swab. The tests are authorized for emergency use by the FDA under an EUA, limited to detection of SARS-CoV-2 nucleic acid and not FDA-cleared or approved.

Section iconCompany Overview

NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2020
Employees
2-10

Section iconFunding & Financials

  • $24M

    Anavasi Diagnostics® has raised a total of $24M of funding over 3 rounds. Their latest funding round was raised on Jan 12, 2022 in the amount of $2.6M as a Convertible Note.

  • $1M - $10M

    Anavasi Diagnostics®'s revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.